AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32967874 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with no training
Number of subjects: 200
Study 36102329 — intervention group
Group type: EXPERIMENTAL
Intervention: OJ + orange pomace (OJ+P, 10g fiber/d)
Number of subjects: 181
Study 36102329 — intervention group
Group type: EXPERIMENTAL
Intervention: AJ + apple pomace (AJ+P, 10g fiber/d)
Number of subjects: 181
Study 36102329 — intervention group
Group type: COMPARATOR
Intervention: OJ (0g fiber/d)
Number of subjects: 181
Study 36102329 — intervention group
Group type: COMPARATOR
Intervention: AJ (0g fiber/d)
Number of subjects: 181
Study 36102329 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange or apple pomace supplementation
Number of subjects: 181
Study 32554185 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Sleep Phase Disorder (DSPD)
Number of subjects: 102
Study 32554185 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening chronotype
Number of subjects: 102
Study 32554185 — intervention group
Group type: EXPERIMENTAL
Intervention: Young age, cannabis use, cyclothymic temperamental traits, severe global impairment
Number of subjects: 102
Study 34746958 — intervention group
Group type: EXPERIMENTAL
Intervention: Falciform ligament wrap around the hepatic artery
Number of subjects: 445
Study 34746958 — intervention group
Group type: COMPARATOR
Intervention: No falciform ligament wrap (control)
Number of subjects: 445
Study 32755526 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk scores for hematocrit
Number of subjects: 493
Study 32755526 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk scores for granulocyte count
Number of subjects: 493
Study 32755526 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk scores for C-reactive protein levels
Number of subjects: 493
Study 35104387 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric MVC
Number of subjects: 39
Study 35104387 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric MVC
Number of subjects: 39
Study 35104387 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric MVC
Number of subjects: 39
Study 35104387 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 34555986 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab plus etesevimab
Number of subjects: 0
Study 34555986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35299753 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance training for 12 weeks during adjuvant chemotherapy
Number of subjects: 106
Study 35299753 — intervention group
Group type: COMPARATOR
Intervention: Education to promote lymphatic and venous return, maintain range of motion, and promote physical activity
Number of subjects: 106
Study 36216140 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI scanning
Number of subjects: 185
Study 36216140 — intervention group
Group type: EXPERIMENTAL
Intervention: rs53576 G homozygotes in the neuroimaging arm
Number of subjects: 185
Study 36216140 — intervention group
Group type: COMPARATOR
Intervention: Behavioral arm
Number of subjects: 185
Study 33963004 — intervention group
Group type: EXPERIMENTAL
Intervention: Prongs
Number of subjects: 50
Study 33963004 — intervention group
Group type: COMPARATOR
Intervention: Nasal mask
Number of subjects: 50
Study 33963004 — intervention group
Group type: EXPERIMENTAL
Intervention: Prongs with leak-corrective manoeuvres
Number of subjects: 50
Study 33963004 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask with leak-corrective manoeuvres
Number of subjects: 50
Study 32030906 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 511
Study 32030906 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 511
Study 32030906 — intervention group
Group type: EXPERIMENTAL
Intervention: Community violence exposure
Number of subjects: 511
Study 32030906 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral problems
Number of subjects: 511
Study 33975171 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 390
Study 33975171 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 390
Study 33975171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 33975171 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline or Paroxetine
Number of subjects: 390
Study 32593323 — intervention group
Group type: EXPERIMENTAL
Intervention: Portico valve
Number of subjects: 750
Study 32593323 — intervention group
Group type: COMPARATOR
Intervention: Commercially available valve
Number of subjects: 750
Study 37779358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone plus intensive lifestyle therapy
Number of subjects: 1936
Study 37779358 — intervention group
Group type: COMPARATOR
Intervention: Conventional lifestyle therapy with placebo
Number of subjects: 1936
Study 37779358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified lifestyle therapy, pioglitazone, or their combination
Number of subjects: 1936
Study 33581774 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib plus capecitabine
Number of subjects: 267
Study 33581774 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib plus capecitabine
Number of subjects: 267
Study 33085711 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to anesthesia and abdominal surgery during infancy
Number of subjects: 485
Study 33085711 — intervention group
Group type: COMPARATOR
Intervention: Control group (unexposed)
Number of subjects: 485
Study 35596146 — intervention group
Group type: EXPERIMENTAL
Intervention: LiHuo probiotics with rabeprazole
Number of subjects: 120
Study 35596146 — intervention group
Group type: COMPARATOR
Intervention: Probiotic placebo with rabeprazole
Number of subjects: 120
Study 33836215 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger portion of vegetables (120 g)
Number of subjects: 67
Study 33836215 — intervention group
Group type: COMPARATOR
Intervention: Flavor enhancement (6.6% light butter and 0.5% salt)
Number of subjects: 67
Study 35067939 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in elaborative reminiscing
Number of subjects: 115
Study 35067939 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study 33887408 — intervention group
Group type: EXPERIMENTAL
Intervention: MF-PRP HD (High Dose)
Number of subjects: 30
Study 33887408 — intervention group
Group type: EXPERIMENTAL
Intervention: MF-PRP LD (Low Dose)
Number of subjects: 30
Study 33887408 — intervention group
Group type: EXPERIMENTAL
Intervention: MF-Saline
Number of subjects: 30
Study 33771832 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee bracing (matched to patients' clinical and radiographic presentation and with adherence support)
Number of subjects: 434
Study 33771832 — intervention group
Group type: COMPARATOR
Intervention: Advice, written information and exercise instruction
Number of subjects: 434
Study 33771832 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee bracing
Number of subjects: 434
Study 35023811 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic 'Haemostasis Traffic Light'
Number of subjects: 84
Study 35023811 — intervention group
Group type: COMPARATOR
Intervention: Text-based cognitive aid
Number of subjects: 84
Study 33876483 — intervention group
Group type: EXPERIMENTAL
Intervention: Silence is Deadly program
Number of subjects: 594
Study 33876483 — intervention group
Group type: COMPARATOR
Intervention: Usual classes
Number of subjects: 594
Study 32273003 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin and Gentamicin (PG)
Number of subjects: 86
Study 32273003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefquinome (CEF)
Number of subjects: 86
Study 32273003 — intervention group
Group type: COMPARATOR
Intervention: Untreated horses (NOAMD)
Number of subjects: 86
Study 34953401 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 0.9% NaCl 500 ml + KCL 20 mEq over 4 h pre-cisplatin 40 mg/m2 weekly for 7-8 weeks (Control group)
Number of subjects: 30
Study 34953401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 0.9% NaCl 500 ml + KCL 20 mEq + additional 16 mEq magnesium (Mg group)
Number of subjects: 30
Study 34210061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ontario Brain Injury Association Peer Support Program (weekly intervention)
Number of subjects: 13
Study 34210061 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 13
Study 32132826 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-closed and weighted multi-ball training (EWMT) for 10 weeks
Number of subjects: 48
Study 32132826 — intervention group
Group type: COMPARATOR
Intervention: Normal training without eye-closed and weighted swing intervention (Control Group)
Number of subjects: 48
Study 32132826 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-closed and weighted multi-ball training (EWMT)
Number of subjects: 48
Study 35562656 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-only intervention
Number of subjects: 150
Study 35562656 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS + pedometer intervention
Number of subjects: 150
Study 35562656 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 150
Study 35689400 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia
Number of subjects: 22
Study 35689400 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 22
Study 34633483 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace bullying exposure
Number of subjects: 1193
Study 34633483 — intervention group
Group type: COMPARATOR
Intervention: Social support
Number of subjects: 1193
Study 35579313 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver antimicrobial dressing in addition to standard of care (SoC) for 2 weeks
Number of subjects: 100
Study 35579313 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) only
Number of subjects: 100
Study 33515785 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention
Number of subjects: 484
Study 33515785 — intervention group
Group type: COMPARATOR
Intervention: Control (risk factors and warning signs)
Number of subjects: 484
Study 34004417 — intervention group
Group type: EXPERIMENTAL
Intervention: New cancer cachexia staging system
Number of subjects: 1325
Study 32531259 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (200 mg) plus ribavirin (200 mg) for 24 weeks
Number of subjects: 38
Study 32531259 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) plus ribavirin (200 mg) for 24 weeks
Number of subjects: 38
Study 32531259 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) plus sofosbuvir (400 mg) for 12 weeks
Number of subjects: 38
Study 36351247 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitch-based musical training (carillon group)
Number of subjects: 61
Study 36351247 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-based musical training (drum group)
Number of subjects: 61
Study 36351247 — intervention group
Group type: COMPARATOR
Intervention: Handcraft learning (control group)
Number of subjects: 61
Study 33781269 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-3 (3 mg/kg/b.m.)
Number of subjects: 21
Study 33781269 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-6 (6 mg/kg/b.m.)
Number of subjects: 21
Study 33781269 — intervention group
Group type: COMPARATOR
Intervention: PLAC (Placebo)
Number of subjects: 21
Study 32199492 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd3‐EBO‐Z/MenACWY‐TT
Number of subjects: 600
Study 32199492 — intervention group
Group type: COMPARATOR
Intervention: MenACWY‐TT/ChAd3‐EBO‐Z
Number of subjects: 600
Study 34984983 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFreedom stent
Number of subjects: 3151
Study 34984983 — intervention group
Group type: COMPARATOR
Intervention: Orsiro stent
Number of subjects: 3151
Study 34449029 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral erector spinae plane block (ESPB)
Number of subjects: 63
Study 34449029 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 36014925 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin administration for 12 weeks
Number of subjects: 27
Study 36014925 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 27
Study 33103603 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon bolus (50 µg/kg)
Number of subjects: 10
Study 33103603 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon infusion (50 µg/kg)
Number of subjects: 10
Study 33103603 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study 33103603 — intervention group
Group type: COMPARATOR
Intervention: Esmolol (1.25 mg/kg bolus + 0.75 mg/kg/min infusion)
Number of subjects: 10
Study 36501128 — intervention group
Group type: EXPERIMENTAL
Intervention: Indulgent breakfast (500 kcal label)
Number of subjects: 50
Study 36501128 — intervention group
Group type: COMPARATOR
Intervention: Sensible breakfast (250 kcal label)
Number of subjects: 50
Study 32484891 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing speed training
Number of subjects: 2097
Study 32484891 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 2097
Study 32484891 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning training
Number of subjects: 2097
Study 32484891 — intervention group
Group type: COMPARATOR
Intervention: No contact control
Number of subjects: 2097
Study 32209625 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (filgrastim)
Number of subjects: 76
Study 32209625 — intervention group
Group type: COMPARATOR
Intervention: Placebo (indistinguishable glucose solution 5%)
Number of subjects: 76
Study 36375780 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of ferric carboxymaltose (FCM)
Number of subjects: 195
Study 36375780 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mL of physiological serum)
Number of subjects: 195
Study 34452671 — intervention group
Group type: EXPERIMENTAL
Intervention: iCALM Telehealth Program
Number of subjects: 40
Study 34452671 — intervention group
Group type: COMPARATOR
Intervention: waitlist
Number of subjects: 40
Study 32339402 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hr ocular dimensional profile recorded with a contact lens sensor (CLS)
Number of subjects: 65
Study 32339402 — intervention group
Group type: COMPARATOR
Intervention: Single tonometric intraocular pressure (IOP) reading
Number of subjects: 65
Study 33387096 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief HRV biofeedback intervention
Number of subjects: 40
Study 33387096 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 33387096 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for biofeedback devices
Number of subjects: 40
Study 36249728 — intervention group
Group type: EXPERIMENTAL
Intervention: U-shaped flap without rolling with temporary crown placement (Group A)
Number of subjects: 40
Study 36249728 — intervention group
Group type: COMPARATOR
Intervention: U-shaped flap with rolling with temporary crown placement (Group B)
Number of subjects: 40
Study 33756064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorinol-containing toothpaste
Number of subjects: 0
Study 33756064 — intervention group
Group type: COMPARATOR
Intervention: Sodium calcium phosphosilicate-containing toothpaste
Number of subjects: 0
Study 32965395 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab plus standard of care
Number of subjects: 0
Study 32965395 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 0
Study 33975807 — intervention group
Group type: EXPERIMENTAL
Intervention: Handout Assisted Consent (HC)
Number of subjects: 79
Study 33975807 — intervention group
Group type: COMPARATOR
Intervention: Verbal Consent (VC)
Number of subjects: 79
Study 33975807 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HC and VC)
Number of subjects: 79
Study 34299960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (educational on healthy habits, nutritional intervention, telematic aerobic and strength exercise)
Number of subjects: 23
Study 34299960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 23
Study 32228177 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating levels of uric acid
Number of subjects: 979
Study 32228177 — intervention group
Group type: COMPARATOR
Intervention: Single polymorphism and accumulation of culprit alleles
Number of subjects: 979
Study 35364413 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation (tVNS) - early stimulation (4 hours daily between Day 0 and 13)
Number of subjects: 68
Study 35364413 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation (tVNS) - late stimulation (4 hours daily between Day 14 and 28)
Number of subjects: 68
Study 35364413 — intervention group
Group type: COMPARATOR
Intervention: Sham tVNS (control condition) - early stimulation
Number of subjects: 68
Study 35364413 — intervention group
Group type: COMPARATOR
Intervention: Sham tVNS (control condition) - late stimulation
Number of subjects: 68
Study 33249449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy and tDCS
Number of subjects: 30
Study 33249449 — intervention group
Group type: COMPARATOR
Intervention: Mirror therapy
Number of subjects: 30
Study 33249449 — intervention group
Group type: COMPARATOR
Intervention: Mirror therapy and sham tDCS
Number of subjects: 30
Study 32228688 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational supports for evidence-based decision making
Number of subjects: 376
Study 32228688 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for inappropriate termination
Number of subjects: 376
Study 32228688 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for inappropriate continuation
Number of subjects: 376
Study 35213547 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab, 200 or 400 mg subcutaneous injection
Number of subjects: 50
Study 35213547 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) alone
Number of subjects: 50
Study 33179398 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-transplantation of bone marrow-derived mesenchymal stem cells (MSCs) with hematopoietic stem cells (HSCs)
Number of subjects: 59
Study 33179398 — intervention group
Group type: COMPARATOR
Intervention: Hematopoietic stem cells (HSCs) only
Number of subjects: 59
Study 36476193 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina (SP) 2 g per day for 5 weeks
Number of subjects: 179
Study 36476193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 36476193 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina (SP)
Number of subjects: 179
Study 32281254 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D U‐Res‐Net_B model
Number of subjects: 122
Study 32281254 — intervention group
Group type: COMPARATOR
Intervention: 3D U‐Res‐Net_O model
Number of subjects: 122
Study 32281254 — intervention group
Group type: COMPARATOR
Intervention: 3D U‐Net model
Number of subjects: 122
Study 35173212 — intervention group
Group type: COMPARATOR
Intervention: Fixed Intensity Group (FG)
Number of subjects: 69
Study 35173212 — intervention group
Group type: COMPARATOR
Intervention: Linear Increase Group (LG)
Number of subjects: 69
Study 35173212 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 69
Study 33751322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot spot cell counting
Number of subjects: 96
Study 33751322 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual estimation of hot spot areas
Number of subjects: 96
Study 33751322 — intervention group
Group type: EXPERIMENTAL
Intervention: Both assessment methods (hot spot cell counting and visual estimation)
Number of subjects: 96
Study 36028908 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples Communication Skills Training (CCST)
Number of subjects: 230
Study 36028908 — intervention group
Group type: COMPARATOR
Intervention: Education control intervention
Number of subjects: 230
Study 33904798 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day antibiotics (ciprofloxacin)
Number of subjects: 824
Study 33904798 — intervention group
Group type: COMPARATOR
Intervention: 3-day antibiotics (ciprofloxacin)
Number of subjects: 824
Study 34798266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleurotus eryngii meal
Number of subjects: 19
Study 34798266 — intervention group
Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 19
Study 34500356 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk Traditional (BT)
Number of subjects: 30
Study 34500356 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk&Go (BG)
Number of subjects: 30
Study 34500356 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk&Flow (BF)
Number of subjects: 30
Study 35340172 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 antibody combined with total neoadjuvant chemoradiotherapy
Number of subjects: 38
Study 35340172 — intervention group
Group type: COMPARATOR
Intervention: Training group model
Number of subjects: 38
Study 35340172 — intervention group
Group type: COMPARATOR
Intervention: Test group model
Number of subjects: 38
Study 34511134 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W plus statin (atorvastatin 20 mg/day or rosuvastatin 10 mg/day)
Number of subjects: 0
Study 34511134 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W plus statin
Number of subjects: 0
Study 34511134 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 33067121 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (mobile health technology-supported care)
Number of subjects: 1261
Study 33067121 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1261
Study 33067121 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (Better symptom management)
Number of subjects: 1261
Study 33851476 — intervention group
Group type: EXPERIMENTAL
Intervention: Guiding Posture
Number of subjects: 172
Study 33851476 — intervention group
Group type: EXPERIMENTAL
Intervention: Guiding Hold
Number of subjects: 172
Study 33851476 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-Handed Forearm Hold
Number of subjects: 172
Study 33851476 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger, Thumb & Wrist Hold
Number of subjects: 172
Study 33851476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupped/Capped Fist Hold
Number of subjects: 172